ViraCore is a biotechnology company that is creating a drug discovery platform for use by the pharmaceutical and biotech industries. Its core technology uses a newly developed optical chip-based technique capable of identifying, measuring and characterizing drug interactions with "membrane-bound receptors," a protein family targeted by 50% of the world's drugs. Current techniques, the presenters explain, are slow and not sensitive enough to detect many important interactions between drugs and the receptors to which they bind. Competitors have simply developed faster ways of using older techniques, whereas ViraCore has developed a novel approach that does not rely only on speeding up outdated technology. The technology will be developed by ViraCore and licensed to other companies for their own drug development efforts
